Mammo_breast_cancer

US-based Rexahn Pharmaceuticals has started dosing patients with Supinoxin in a Phase I clinical trial to evaluate the drug safety and effectiveness profile in patients suffering from solid cancer tumours.

Also known as RX-5902, Supinoxin can be administered orally in patients and is a molecule inhibitor of phosphorylated-p68 RNA helicase (P-p68), which is found only in cancer cells and increases the activity of several cancer linked genes such as cyclin D1, c-jun and c-myc.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

P-p68 has been found to have over-expression in solid tumour cases such as of melanoma, colon, ovarian and lung and aids in tumour progression and metastasis.

Rexahn chief executive officer Dr Peter Suzdak said: "Supinoxin is Rexahn’s third oncology compound to enter into clinical development and represents an important part of our expanding clinical development pipeline."

Conducted in multiple centres, the dose-escalation Phase I study will evaluate the safety, tolerability, toxicities and maximal tolerated dose (MTD) in patients.

See Also:

Secondary endpoints of the study will comprise pharmacokinetic profile characterisation of the drug and studying the initial anti-tumour effects.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Supinoxin has shown an ability to restrict the growth in 18 human cancer cell lines such as those of breast, colon, pancreas, ovarian, and stomach cancers, and also in drug-resistant cancer cells in preclinical studies.

Greenville Health Systems Institute for Translational Oncology Research (ITOR) medical director Dr Joe Stephenson said that Supinoxin represented an interesting approach for the treatment of cancer patients with solid tumours.

Image: Mammograms of a normal breast (left) and a cancerous breast (right). Photo: courtesy of the National Cancer Institute.